Dose- and genotype-dependent cardiac arrhythmia and sudden death in rats following microdystrophin gene therapy

Authors
Caroline Le Guiner, Gilles Toumaniantz, Thibaut Larcher, Sylvie Marchand, Laurine Buscara, Grégory Cedrone, Cladice Varela Moreira, Amandine Lancelot, Christophe Georger, Aude Lafoux, Célia Couzinié, David Augereau, Corinne Jounier, Agnès Hivonnait, Estelle Creoff, Stéphanie Blaie, Corinne Huchet, Oumeya Adjali, Nathalie Daniele, Gérald Perret, Serge Braun


Lab
UMR 703; PanTher; APEX; 91000 Evry; 91000 Evry; 91000 Evry

Journal
Molecular Therapy

Abstract

Recombinant adeno-associated virus (rAAV) vectors encoding microdystrophin (MD) are a promising treatment for Duchenne muscular dystrophy (DMD). GNT0004, an rAAV2/8 vector expressing MD1, is currently being tested in patients with DMD. Here, we explored supra-optimal intravenous doses of GNT0004 (2.1 × 1014 and 4.2 × 1014 vg/kg, up to 14 times the therapeutic dose) in wild-type (WT) and DMDmdx rats. In all cohorts, robust MD1 protein expression was observed. In DMD animals, creatine kinase levels were normalized, and skeletal muscle and heart histology and functions were improved. However, unexpected sudden deaths occurred at the highest dose. In WT animals, deaths were observed at both doses and were associated with increased arrhythmic events, which may promote structural and functional heart issues. Immunohistological analysis suggested that overexpression of MD1 may disrupt the dystrophin-associated protein complex, increasing the risk of arrhythmias and sudden death. In DMDmdx rats, the 2.1 × 1014 vg/kg dose was well tolerated, but some deaths occurred at 4.2 × 1014 vg/kg, for which a causal link to GNT0004 cannot be excluded. At this dose, increased arrhythmic risk and cardiac pathological remodeling were observed. These observations highlight the potential risk of MD overexpression in the heart and suggest a need for careful monitoring of patients with DMD treated with gene therapy.

Keywords/Topics
Duchenne muscular dystrophy; gene therapy; rAAV; microdystrophin; DMDmdx rat; overexpression; sudden death; cardiac arrhythmia

BIOSEB Instruments Used:
Grip strength test (BIO-GS4)

Source :

https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(25)00862-7

Produits associés

Test d'agrippement

DEMANDE DE PUBLICATION

Merci de votre intérêt pour notre gamme de produits et de votre demande pour cette publication qui vous sera envoyée si l'équipe de recherche et la revue le permettent. Notre équipe commerciale vous contactera dans les plus brefs délais.